Jeff Jones, Cullinan Oncology CMO

#AS­CO22: With me­di­an dura­bil­i­ty da­ta, Cul­li­nan aims to 'dis­tin­guish it­self' from Takeda's Exkiv­i­ty and J&J's Ry­bre­vant in ex­on 20 NSCLC

CHICA­GO — In its “first time on a big­ger stage” at this week­end’s AS­CO con­fer­ence, Cul­li­nan On­col­o­gy thinks it has the da­ta to “dis­tin­guish it­self” …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.